Help at hand for RRMS patients

A revolutionary research study hints at the evidence that COPAXONE? (glatiramer acetate injection) may offer protection from axonal injury and induced neuronal metabolic recovery in patients with relapsing remitting multiple sclerosis (RRMS). // COPAXONE? (glatiramer acetate injection) is a s...

New Data Suggests Progression of Disability at Two Years Predicts Multiple Sclerosis (MS) Disability Progression at Eight Years

...an Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Prague, Czech Republic. The analysis involved 160 patients with rrms who received at least two years of treatment (81 placebo, 79 interferon beta-1a), in the AVONEX Phase III trial and who were re-examined eight years p...

RRMS in Medical Technology

ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis

...ibit the production of VLA-4 could significantly reduce disease activity in rrms patients as early as 8 weeks. The level of efficacy achieved by ATL/TV1102 ...target VLA-4 and therefore presents an exciting future treatment option for rrms patients." Mark Diamond, Chief Executive Officer of Antisense Therapeutic...

MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial

...mon type of the disease, affects approximately 65% of MS patients according to a Cognos study published by Decision Resources, Inc. Most patients with rrms eventually progress to the secondary progressive (SPMS) form of the disease. MN-166 is a novel, orally administered compound being evaluated for the...

First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

...lity of data demonstrating the long-term treatment outcomes of immunomodulatory therapies in MS allowed us to assess the cost-effectiveness of various rrms treatment strategies. Findings of this study indicated that of the four therapies used to manage MS and in comparison with symptom management alone, t...

Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)

...n a recent issue of Neurology. The study can be accessed at: http://www.neurology.org/cgi/content/abstract/68/12/939. "COPAXONE(R) is an established rrms therapy with more than 12 years of clinical research and experience supporting its efficacy and safety. The recently published data demonstrated that ...

Data on Higher Dose of Copaxone and Data Showing Copaxone is Most Cost Effective

...http://www.neurology.org/cgi/content/abstract/68/12/939">http://www.neurology.org/cgi/content/abstract/68/12/939 . "COPAXONE is an established rrms therapy with more than 12 years of clinical research and experience supporting its efficacy and safety. The recently published data demonstrated that ...

Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

...bo. These data were presented at the 59th Annual Meeting of the American Academy of Neurology (AAN) in Boston, MA, April 28 - May 5, 2007. "Current rrms options are effective for the treatment of the disease, but an oral therapy such as laquinimod would represent a milestone for patients as it would pr...

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

...cted and analyzed through 48 weeks. About MS and rrms MS is a chronic autoimmune disease of the centra...toms and different courses of disease progression. rrms is the most common form of MS, accounting for appr...recovery from relapse is incomplete, patients with rrms gradually accumulate irreversible neurological dam...

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

...ted and analyzed through 48 weeks. About MS and rrms MS is a chronic autoimmune disease of the centra...toms and different courses of disease progression. rrms is the most common form of MS, accounting for appr...recovery from relapse is incomplete, patients with rrms gradually accumulate irreversible neurological dam...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

...rosis has undergone a prospective, controlled, multi- year, head-to-head comparison to a recommended first-line therapy. In the trial, patients with rrms at 49 medical centers in Europe and in the U.S. were treated with alemtuzumab at one of two doses (12 or 24 mg IV per day for five days at initial tre...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

...ved at 15 months with COPAXONE(R) after brief mitoxantrone therapy was maintained with continued COPAXONE(R) at 24 months. The original study included rrms patients (n=40), ages 18-55, who had at least one Gd-enhancing lesion at the time of the screening MRI and an Expanded Disability Status Scale (EDSS) ...